Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference
Liquidia (NASDAQ: LQDA) has announced three poster presentations at the upcoming American Thoracic Society (ATS) 2025 International Conference in San Francisco, scheduled for May 18-21, 2025.
Two posters will present new data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients, focusing on safety, tolerability, and exploratory changes in 6-minute walk distance, quality of life, and cardiac effort. The third poster features a case study from the INSPIRE study, examining long-term safety and tolerability in a PAH patient transitioning from parenteral treprostinil.
The presentations are scheduled for Tuesday, May 20, 2025, from 11:30 a.m. to 1:15 p.m. PT, with Dr. Rajan Saggar, Dr. Daniel Lachant, and Dr. Rodolfo Estrada as presenting authors. All posters will be available on Liquidia's website after the presentations.
Liquidia (NASDAQ: LQDA) ha annunciato tre presentazioni di poster alla prossima Conferenza Internazionale della Società Toracica Americana (ATS) 2025 che si terrà a San Francisco, dal 18 al 21 maggio 2025.
Due poster presenteranno nuovi dati dallo studio ASCENT su LIQ861 (YUTREPIA™) in pazienti con PH-ILD, concentrandosi su sicurezza, tollerabilità e cambiamenti esplorativi nella distanza percorsa in sei minuti, qualità della vita e sforzo cardiaco. Il terzo poster presenta uno studio di caso dallo studio INSPIRE, esaminando la sicurezza e tollerabilità a lungo termine in un paziente con PAH in transizione da treprostinil parenterale.
Le presentazioni sono programmate per martedì 20 maggio 2025, dalle 11:30 alle 13:15 PT, con il Dr. Rajan Saggar, il Dr. Daniel Lachant e il Dr. Rodolfo Estrada come autori presentatori. Tutti i poster saranno disponibili sul sito web di Liquidia dopo le presentazioni.
Liquidia (NASDAQ: LQDA) ha anunciado tres presentaciones de pósteres en la próxima Conferencia Internacional de la Sociedad Torácica Americana (ATS) 2025 que se llevará a cabo en San Francisco, del 18 al 21 de mayo de 2025.
Dos pósteres presentarán nuevos datos del estudio ASCENT sobre LIQ861 (YUTREPIA™) en pacientes con PH-ILD, centrándose en la seguridad, tolerabilidad y cambios exploratorios en la distancia de caminata de seis minutos, calidad de vida y esfuerzo cardíaco. El tercer póster presenta un estudio de caso del estudio INSPIRE, examinando la seguridad y tolerabilidad a largo plazo en un paciente con PAH que transiciona de treprostinilo parenteral.
Las presentaciones están programadas para el martes 20 de mayo de 2025, de 11:30 a.m. a 1:15 p.m. PT, con el Dr. Rajan Saggar, el Dr. Daniel Lachant y el Dr. Rodolfo Estrada como autores presentadores. Todos los pósteres estarán disponibles en el sitio web de Liquidia después de las presentaciones.
리퀴디아 (NASDAQ: LQDA)는 2025년 5월 18일부터 21일까지 샌프란시스코에서 열리는 미국 호흡기학회(ATS) 2025 국제 회의에서 세 개의 포스터 발표를 발표한다고 발표했습니다.
두 개의 포스터는 PH-ILD 환자에서 LIQ861 (YUTREPIA™)의 ASCENT 연구에서 새로운 데이터를 제시하며, 안전성, 내약성 및 6분 보행 거리, 삶의 질, 심장 노력의 탐색적 변화를 중심으로 합니다. 세 번째 포스터는 INSPIRE 연구의 사례 연구를 다루며, 정맥 주사형 트레프로스틴일에서 전환하는 PAH 환자의 장기 안전성과 내약성을 조사합니다.
발표는 2025년 5월 20일 화요일 오전 11:30부터 오후 1:15까지 PT로 예정되어 있으며, 발표 저자는 Rajan Saggar 박사, Daniel Lachant 박사, Rodolfo Estrada 박사입니다. 모든 포스터는 발표 후 리퀴디아 웹사이트에서 확인할 수 있습니다.
Liquidia (NASDAQ: LQDA) a annoncé trois présentations de posters lors de la prochaine Conférence Internationale de la Société Thoracique Américaine (ATS) 2025 qui se tiendra à San Francisco, du 18 au 21 mai 2025.
Deux posters présenteront de nouvelles données de l'étude ASCENT sur LIQ861 (YUTREPIA™) chez des patients atteints de PH-ILD, en mettant l'accent sur la sécurité, la tolérance et les changements exploratoires dans la distance de marche de six minutes, la qualité de vie et l'effort cardiaque. Le troisième poster présente une étude de cas de l'étude INSPIRE, examinant la sécurité et la tolérance à long terme chez un patient atteint de PAH en transition d'un traitement par tréprostinil par voie parentérale.
Les présentations sont prévues pour le mardi 20 mai 2025, de 11h30 à 13h15 PT, avec le Dr Rajan Saggar, le Dr Daniel Lachant et le Dr Rodolfo Estrada en tant qu'auteurs présentateurs. Tous les posters seront disponibles sur le site Web de Liquidia après les présentations.
Liquidia (NASDAQ: LQDA) hat drei Posterpräsentationen auf der bevorstehenden Internationalen Konferenz der American Thoracic Society (ATS) 2025 in San Francisco angekündigt, die vom 18. bis 21. Mai 2025 stattfindet.
Zwei Poster präsentieren neue Daten aus der ASCENT-Studie zu LIQ861 (YUTREPIA™) bei PH-ILD-Patienten, wobei der Fokus auf Sicherheit, Verträglichkeit und explorativen Veränderungen der Gehstrecke in sechs Minuten, Lebensqualität und Herzbelastung liegt. Das dritte Poster zeigt eine Fallstudie aus der INSPIRE-Studie, die die langfristige Sicherheit und Verträglichkeit bei einem PAH-Patienten untersucht, der von parenteralem Treprostinil wechselt.
Die Präsentationen sind für Dienstag, den 20. Mai 2025, von 11:30 bis 13:15 Uhr PT geplant, mit Dr. Rajan Saggar, Dr. Daniel Lachant und Dr. Rodolfo Estrada als präsentierende Autoren. Alle Poster werden nach den Präsentationen auf der Website von Liquidia verfügbar sein.
- None.
- None.
- Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life
- Case study highlights the long-term safety and tolerability of LIQ861 (YUTREPIA) in a PAH patient transitioning from parenteral treprostinil in INSPIRE study
MORRISVILLE, N.C., March 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the company will present three posters at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025, in San Francisco. Two posters will highlight new data from the company’s open-label ASCENT study of LIQ861 (YUTREPIA) in PH-ILD patients with a focus on safety, tolerability, exploratory changes in 6-minute walk distance, quality of life, and changes in cardiac effort. A third poster is a case study of a patient with PAH participating in the open-label extension study (INSPIRE).
Poster Discussion Session: Poster Board #1404
Date and time: Tuesday, May 20, 2025 from 11:30 a.m. – 1:15 p.m. PT
Presenting Author: Rajan Saggar, MD
Abstract: An ASCENT to Week 8: Initial Safety and Exploratory Efficacy Data on LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD Patients
Poster Discussion Session: Poster Board #1401
Date and time: Tuesday, May 20, 2025 from 11:30 a.m. – 1:15 p.m. PT
Presenting Author: Daniel Lachant, MD
Abstract: Changes in Cardiac Effort in Pulmonary Hypertension-Interstitial Lung Disease: Insights From the ASCENT Trial
Poster Discussion Session: Poster Board #1464
Date and time: Tuesday, May 20, 2025 from 11:30 a.m. – 1:15 p.m. PT
Presenting Author: Rodolfo Estrada, MD
Abstract: Transitioning From Parenteral Treprostinil to LIQ861 in a Patient With PAH
Following the presentations, each poster will be available on the Publications page of Liquidia’s website at https://liquidia.com/publications.
About YUTREPIA™ (treprostinil) Inhalation Powder
YUTREPIA is an investigational, inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. In August 2024, the FDA issued tentative approval of YUTREPIA for the PAH and PH-ILD indications. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso® (nebulized treprostinil). YUTREPIA is currently being studied in the ASCENT trial, an Open-Label Prospective Multicenter Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension, with the objective of informing YUTREPIA’s dosing and tolerability profile in patients with PH-ILD. YUTREPIA was previously referred to as LIQ861 in investigational studies.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
What data will Liquidia (LQDA) present at ATS 2025 regarding YUTREPIA?
When and where will Liquidia (LQDA) present their YUTREPIA research at ATS 2025?
What are the main studies being presented about LQDA's YUTREPIA at ATS 2025?
Who are the presenting authors for LQDA's YUTREPIA posters at ATS 2025?
